Corvus Pharmaceuticals (CRVS) Reiterated at Overweight by Cantor Fitzgerald
September 16, 2026 7:42 AM
Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and {REMOVEPT} price target on Corvus Pharmaceuticals (NASDAQ: CRVS).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
